Citigroup’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Citigroup’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-55,500	Closed	-$690K	–	7519
2016 Q4	$690K	Sell	55,500 -29,100	-34%	-$350K	﹤0.01%	4050
2016 Q3	$1.16M	Buy	84,600 +19,400	+30%	+$195K	﹤0.01%	3066
2016 Q2	$482K	Buy	65,200 +23,200	+55%	+$174K	﹤0.01%	3702
2016 Q1	$268K	Sell	42,000 -17,100	-29%	-$95.8K	﹤0.01%	4809
2015 Q4	$369K	Sell	59,100 -3,000	-5%	-$19.7K	﹤0.01%	4182
2015 Q3	$363K	Buy	62,100 +25,900	+72%	+$200K	﹤0.01%	4045
2015 Q2	$299K	Buy	+36,200	New	+$320K	﹤0.01%	4134

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Citigroup's ARIA Position: Q1 2017 in Review

Citigroup sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 777,786 shares — an estimated $9.68M sold.

Citigroup first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $9.68M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

Citigroup reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Citigroup sold 777,786 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $9.68M.
Citigroup first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
Citigroup's Ariad Pharmaceuticals Inc position peaked at $9.68M in Q4 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Citigroup's 13F filing for Q1 2017, filed 12 May 2017.